Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BeiGene's Brukinsa Fails In Head-To-Head But Hope Remains For Rare Indication

Signs Of Benefit Vs Imbruvica

Executive Summary

Days after bagging a US approval for its first global new drug, BeiGene was dealt a blow as its BTK inhibitor Brukinsa showed no significant superiority over class leader Imbruvica in Waldenström's macroglobulinemia, although the Chinese company remains hopeful for a possible approval.

You may also be interested in...



After US Approval, BeiGene Set To Gain Sixth PD-1 Green Light In China

Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.

Keeping Track Of User Fee Decisions And Filings: Adakveo, Brukinsa And Fetroja Mark Massive Week Of Novel Approvals

The latest news on US FDA user fee decisions and submissions to the agency.

China's New Hong Kong Security Law To Derail Biotech IPOs?

A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel